What is the primary purpose of these amendments to the collaboration agreements?

The primary purpose is to extend and enhance the strategic collaboration between Regeneron and Sanofi for discovering, developing, and commercializing therapeutic antibodies. Key changes include extending the program duration, increasing Sanofi's financial commitment, and modifying terms related to milestones and exclusivity.

How does the increase in Sanofi's funding impact Regeneron?

The increase in Sanofi's annual reimbursement for the Discovery Program from $100 million to $160 million provides Regeneron with substantially more capital to fund its research and development activities related to antibody discovery and validation. This demonstrates Sanofi's continued confidence and commitment to the partnership.

What is the significance of extending Sanofi's lock-up period?

Extending the lock-up period for Sanofi's investment in Regeneron's common stock for another five years indicates Sanofi's long-term strategic interest in Regeneron. It provides stability for Regeneron's stock by limiting immediate sell-offs from a major shareholder and reinforces the deep partnership between the two companies.

Are there any changes to how antibodies developed outside the collaboration can be handled?

Yes, the exclusivity provisions have been amended to give Sanofi additional flexibility to license and develop antibodies outside of this specific collaboration, under certain conditions. This could potentially lead to new development opportunities for Sanofi.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 12, 2009, detailing material amendments to its collaboration agreements with sanofi-aventis ('Sanofi') and an associated investor agreement. These amendments significantly extend and enhance the global strategic collaboration focused on discovering, developing, and commercializing therapeutic antibodies using Regeneron's VelociSuite technologies. The core of the announcement involves a five-year extension of the Discovery Program through December 31, 2017, with an option for Sanofi to extend further. Notably, Sanofi's annual reimbursement for this program was increased from $100 million to $160 million, reflecting a deepened commitment and expanded scope. Additionally, the agreement includes provisions for milestone payments on antibody candidates derived from new technologies and Sanofi's commitment to fund facility expansions for Regeneron's manufacturing capabilities. Furthermore, the lock-up period for Sanofi's significant investment in Regeneron's common stock was extended by an additional five years, running until December 20, 2017. These amendments signal a strong, long-term partnership and increased financial support from Sanofi, crucial for Regeneron's continued research and development efforts.

Key Highlights

1Regeneron and Sanofi have extended their global antibody discovery and development collaboration through December 31, 2017, with potential for further extension.
2Sanofi's annual funding commitment for the Discovery Program has been increased from $100 million to $160 million per year.
3Sanofi has the option to extend certain antibody development and preclinical activities for up to three additional years beyond the initial extension.
4Regeneron is eligible to receive $10 million milestone payments for antibody product candidates licensed by Sanofi that utilize new antibody technologies developed by Regeneron.
5Sanofi will reimburse up to $30 million for the expansion of Regeneron's antibody manufacturing facilities in Rensselaer, New York.
6The lock-up period for Sanofi's investment in Regeneron's common stock has been extended by an additional five years, ending on December 20, 2017.
7The amendments provide Sanofi with increased flexibility to license and develop antibodies outside of the collaboration.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Nov 12, 2009)

Summary

Key Highlights

Frequently Asked Questions